Pharma & Bio
Lifestyle
Is Investor Sentiment Returning? Even the 'Troublesome Trio' Makes the 'Top 15 Stock Gainers' [Bio Spotlight]
As the domestic securities market has recently entered a correction phase, a trend has been observed in which capital, having lost its direction, is once again flowing back into the pharmaceutical and…
Lifestyle
"From Efficacy Failures to Controversy Over Internal Analysis"... Kolon TissueGene's U.S. Phase 3 Trial Objectivity Under Scrutiny
Kolon TissueGene CI (Photo courtesy of Kolon TissueGene)
Kolon TissueGene’s TG-C, a cell-gene therapy for osteoarthritis, failed to demonstrate efficacy in the first topline results from its U.S. …
Technology
'KOLON CORPORATION's Fourth Child' TG-C Fails U.S. Phase 3 Trial… 27-Year Quest for a New Drug 'Shaken'
#KOLON CORPORATION’s “TG-C,” a cell- and gene-based therapy for osteoarthritis that the company has been developing for 27 years, has failed its U.S. Phase 3 clinical trial. TG-C is a new drug to whic…
Lifestyle
Celltrion and Samsung, Not SMEs, Benefit from Biosimilar Phase 3 Exemption... Why?
With the official announcement of the Phase 3 clinical trial exemption for biosimilars, biosimilar companies are busy crunching the numbers. On the 14th, South Korea’s Ministry of Food and Drug Safety…
Technology
Kim Mi-hyung, CEO of ANTEROGEN CO., LTD.: “Over 1,000 Potential Patients for Alostemcit in Japan”
Ahead of the inclusion of “Alostemcit,” a treatment for epidermolysis bullosa, in Japan’s national health insurance reimbursement list, ANTEROGEN CO., LTD.(065660)has estimated the number of potential…
KOSDAQ
Samick Pharm Hits Daily Limit-Up on Hair Loss Theme; Kolon TissueGene and Lemon Healthcare Plunge [K-Bio Pulse]
South Korean pharmaceutical and biotech stocks posted mixed results on Wednesday. Samick Pharm surged to the daily limit as investors focused on its long-acting injectable platform technology, while O…
KOSDAQ
Hair Loss-Themed SAMIK PHARM. Co., LTD. Rises… Kolon TissueGene, Inc. and LEMON COMPANY LIMITED Down Over 20% [Bio Market Watch]
On the 16th, the domestic pharmaceutical and biotech sector saw mixed performance across individual stocks. #SAMIK PHARM. Co., LTD. hit the daily price limit, driven by its long-acting injectable plat…
Disclosure Plus
Pfizer Places Additional Order for Research Services on D&D Pharmatech Inc.’s Weight-Loss Drug… What Does This Mean?
D&D Pharmatech Inc.(347850)has secured an additional order from U.S.-based Pfizer related to the development of an oral obesity treatment formulation. Although the increase in the contract value amoun…
Lifestyle
[Blue Ocean Veterinary Medical Devices] ① Jeong Byeong-gon, President of the Korea Veterinary Medicines Association: “Focus on ‘Animal-Specific’ Products Derived from Human Medicines”
As medical technology advances, the treatment of human diseases is rapidly evolving into the era of “personalized medicine” and “precision medicine.” This shift is now spreading to the field of veteri…
Technology
Bin Jun-gil, CEO of NEUROPHET Inc.: "We Seized the 'Stroke' Market While Competitors Focused on Mild Conditions... on the Verge of Doubling Revenue"
The brain is like the most sophisticated electronic circuit in the human body. Imbalances in minute electrical signals can lead to life-threatening and severe diseases such as stroke, dementia, and de…